Retention rates were
similar in the two groups; 53 topiramate recipients and 52 placebo
recipients remained in the study as of week 6. Note that week 6
was the beginning of the period for the primary outcome at which
subjects achieved maximum tolerated doses. Likewise, 39 topiramate
recipients and 38 placebo recipients completed the entire 12
weeks of treatment.